Roche Holding AG has heralded late-stage data on a subcutaneous (SC) version of Ocrevus which will allow the multiple sclerosis blockbuster to be administered in just 10 minutes twice a year, boosting uptake of the drug and potentially blunting the commercial prospects for TG Therapeutics, Inc.'s recently approved competitor Briumvi.
Roche Touts 10-Minute Ocrevus Benefits For MS
Filings Imminent
A subcutaneous version of Ocrevus is as effective as the intravenous form of Roche's biggest seller, and could boost access of the multiple sclerosis drug where access to intravenous clinics is problematic.
More from Neurological
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
More from Therapy Areas
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.